Iovance Biotherapeutics (IOVA) Interest Coverage Ratio (2011 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Interest Coverage Ratio of 0.03 for Q1 2026, up 99.43% year-over-year from 0.02 in Q1 2025, and up 99.83% quarter-over-quarter from 18.98 in Q4 2025.
Iovance Biotherapeutics (IOVA) Interest Coverage Ratio (2011 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Interest Coverage Ratio for 16 consecutive years, with 0.03 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 99.43% year-over-year to 0.03; the TTM figure through Mar 2026 stood at 0.14 (up 99.22% YoY), while the FY2025 annual figure was 0.45, up 89.36% from the prior year.
- Interest Coverage Ratio advanced to 0.03 in Q1 2026 per IOVA's latest filing, from 18.98 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 14.74 in Q4 2022 and bottomed at 30.57 in Q2 2022.
- Historically, Interest Coverage Ratio has averaged 6.26 across 5 years, with a median of 3.32 in 2022.
- Annual changes were most pronounced in 2023 — Interest Coverage Ratio soared 99.44% — and 2024, when it sank 9510.01%.
- Iovance Biotherapeutics' Interest Coverage Ratio stood at 14.74 in 2022, then retreated by 4.39% to 14.09 in 2023, then sank by 222.0% to 17.19 in 2024, then slipped by 10.36% to 18.98 in 2025, then surged by 99.83% to 0.03 in 2026.
- Business Quant data shows IOVA's Interest Coverage Ratio at 0.03 in Q1 2026, 18.98 in Q4 2025, and 0.61 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | -0.01 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.01 |
| Mar 31, 2026 | -0.03 |
| Dec 31, 2025 | -18.98 |
| Sep 30, 2025 | -0.61 |
| Jun 30, 2025 | -1.32 |
| Mar 31, 2025 | -5.51 |
| Dec 31, 2024 | -17.19 |
| Sep 30, 2024 | -3.92 |
| Jun 30, 2024 | -16.36 |
| Mar 31, 2024 | -1.98 |
| Dec 31, 2023 | 14.09 |
| Sep 30, 2023 | -7.79 |
| Jun 30, 2023 | -0.17 |
| Mar 31, 2023 | -0.64 |
| Dec 31, 2022 | 14.74 |
| Sep 30, 2022 | -26.93 |
| Jun 30, 2022 | -30.57 |
| Mar 31, 2022 | -3.32 |
| Dec 31, 2021 | 15.94 |
| Sep 30, 2021 | -23.92 |